Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC8A1 | P32418 | 7/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.39 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687992 | 0.99 | SLC8A1 (0.43) | SLC8A1CRBNKCNH2HRH3TAOK1 | |
| SCHEMBL10070887 | 0.83 | SLC8A1 (0.41) | SLC8A1CRBNKCNH2HRH3 | |
| SCHEMBL1688052 | 0.81 | KCNH2 (0.39) | CRBNKCNH2HRH3TAOK1TAOK3 | |
| SCHEMBL11045895 | 0.79 | SLC8A1 (0.47) | SLC8A1 | |
| SCHEMBL1687994 | 0.76 | ESR2 (0.57) | KMT2ALTA4H | |
| SCHEMBL1688018 | 0.75 | ESR2 (0.56) | KMT2ALTA4H | |
| SCHEMBL6565400 | 0.74 | MAOB (0.49) | SLC8A1 | |
| SCHEMBL11050225 | 0.73 | MAOB (0.58) | SLC8A1KMT2A | |
| SCHEMBL29974186 | 0.73 | MAOB (0.58) | SLC8A1KMT2A | |
| SCHEMBL8754519 | 0.69 | LMNA (0.51) | CRBNLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101651-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
| WO-2009055734-A1 | CONDENSED COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | SLC8A1 1339/4885CRBN 4109/4885KCNH2 3697/4885 |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | SLC8A1 1339/4885CRBN 4109/4885KCNH2 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.